Next Article in Journal
Immunotherapy in Extensive-Stage Small Cell Lung Cancer
Previous Article in Journal
Recent Advances in Photodynamic Imaging and Therapy in Hepatobiliary Malignancies: Clinical and Experimental Aspects
Previous Article in Special Issue
Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients
Article

Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer

1
Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
2
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(5), 4080-4092; https://doi.org/10.3390/curroncol28050346 (registering DOI)
Received: 17 September 2021 / Revised: 24 September 2021 / Accepted: 8 October 2021 / Published: 12 October 2021
(This article belongs to the Special Issue Translational Research in Breast Cancer Patients)
Background: Accumulating evidence indicates tumor-promoting roles of synaptotagmin 13 (SYT13) in several cancers; however, no studies have investigated its expression in breast cancer (BC). This study aimed to clarify the significance of SYT13 in BC. Methods: SYT13 mRNA expression levels were evaluated in BC cell lines. Polymerase chain reaction (PCR) array analysis was conducted to determine the correlation between expression levels of SYT13 and other tumor-associated genes. Then, the association of SYT13 expression levels in the clinical BC specimens with patients’ clinicopathological factors was evaluated. These findings were subsequently validated using The Cancer Genome Atlas (TCGA) database. Results: Among 13 BC cell lines, estrogen receptor (ER)-positive cells showed higher SYT13 mRNA levels than ER-negative cells. PCR array analysis revealed positive correlations between SYT13 and several oncogenes predominantly expressed in ER-positive BC, such as estrogen receptor 1, AKT serine/threonine kinase 1, and cyclin-dependent kinases 4. In 165 patients, ER-positive specimens exhibited higher SYT13 mRNA expression levels than ER-negative specimens. The TCGA database analysis confirmed that patients with ER-positive BC expressed higher SYT13 levels than ER-negative patients. Conclusion: This study suggests that SYT13 is highly expressed in ER-positive BC cells and clinical specimens, and there is a positive association of SYT13 with the ER signaling pathways. View Full-Text
Keywords: breast cancer; SYT13; estrogen receptor; progesterone receptor breast cancer; SYT13; estrogen receptor; progesterone receptor
Show Figures

Figure 1

MDPI and ACS Style

Ichikawa, T.; Shibata, M.; Inaishi, T.; Soeda, I.; Kanda, M.; Hayashi, M.; Takano, Y.; Takeuchi, D.; Tsunoda, N.; Kodera, Y.; Kikumori, T. Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer. Curr. Oncol. 2021, 28, 4080-4092. https://doi.org/10.3390/curroncol28050346

AMA Style

Ichikawa T, Shibata M, Inaishi T, Soeda I, Kanda M, Hayashi M, Takano Y, Takeuchi D, Tsunoda N, Kodera Y, Kikumori T. Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer. Current Oncology. 2021; 28(5):4080-4092. https://doi.org/10.3390/curroncol28050346

Chicago/Turabian Style

Ichikawa, Takahiro, Masahiro Shibata, Takahiro Inaishi, Ikumi Soeda, Mitsuro Kanda, Masamichi Hayashi, Yuko Takano, Dai Takeuchi, Nobuyuki Tsunoda, Yasuhiro Kodera, and Toyone Kikumori. 2021. "Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer" Current Oncology 28, no. 5: 4080-4092. https://doi.org/10.3390/curroncol28050346

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop